anti-tnbc agent-1

anti-TNBC agent-1 is a highly effective compound specifically targeting and combating triple-negative breast cancer (TNBC), demonstrating remarkable potency against various breast cancer cell types with IC50 values ranging from 0.20 μM to 0.27 μM. Its mechanism of action involves inducing apoptosis in SUM-159 cells through the mitochondria pathway and causing G1 phase arrest in these cells.

Anti-TNBC agent-10 is an agent targeting triple-negative breast cancer (TNBC). It demonstrates potent anti-TNBC activity against BT549 cells with an IC50 of 0.018 μM and remains active in MDA-MB-231 cells with an IC50 of 4.16 μM. In mice with subcutaneous MDA-MB-231 TNBC xenografts, it shows significant antitumor efficacy. Anti-TNBC agent-10 is applicable in TNBC studies.

anti-TNBC agent-12 (Compound 23a) is a multi-targeted anticancer agent that inhibits HDAC6 with an IC50 of 30.3 nM and targets DNA, while also inducing the release of nitric oxide (NO). It promotes tumor cell apoptosis and causes cell cycle arrest at the G2/M phase. anti-TNBC agent-12 is a potential candidate for the study of triple-negative breast cancer (TNBC).

Anti-TNBC agent-13 is a NO donor-Aurovertin B conjugate that can induce ferroptosis. It inhibits GPX4 activity, leading to cell death in triple-negative breast cancer (TNBC) cells. Anti-TNBC agent-13 is useful for research in triple-negative breast cancer.

Anti-TNBC agent-14 (Compound 4l) is a selective agent targeting triple-negative breast cancer. It functions as a potent and selective DNA-binding agent, capable of inducing caspase-3 dependent apoptosis (Apoptosis) and mitochondrial ROS generation (mitochondrial).